Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shar...
December 12 2018 - 4:05PM
Synthorx, Inc. (Nasdaq: THOR), a biotechnology company using a
first-of-its-kind Expanded Genetic Alphabet platform technology to
discover and develop optimized biologics for cancer and autoimmune
disorders, today announced the closing of its previously announced
initial public offering of 13,699,636 shares of common stock, which
includes the exercise in full of the underwriters’ option to
purchase 1,786,909 additional shares of common stock, at a public
offering price of $11.00 per share. The aggregate gross proceeds to
Synthorx from the offering, before deducting underwriting discounts
and commissions and other offering expenses, were $150.7
million. All of the shares in the offering were offered by
Synthorx. The shares commenced trading on the Nasdaq Global
Select Market on December 7, 2018 under the ticker symbol
“THOR.”
Jefferies LLC, Leerink Partners LLC and Evercore ISI acted as
joint book-running managers for the offering. H.C. Wainwright &
Co., LLC acted as lead manager for the offering.
Registration statements relating to these securities have been
filed with the Securities and Exchange Commission and became
effective on December 6, 2018. Copies of the final prospectus
relating to the offering may be obtained from: Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022 or by telephone at (877)
547-6340 or by email at Prospectus_Department@Jefferies.com;
Leerink Partners LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, or by telephone at (800)
808-7525, ext. 6132 or by email at syndicate@leerink.com; or
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, New York, NY 10055 or by telephone at (888) 474-0200
or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About SynthorxSynthorx, Inc. is a biotechnology
company focused on prolonging and improving the lives of people
with cancer and autoimmune disorders. Synthorx’s proprietary,
first-of-its-kind Expanded Genetic Alphabet platform technology
expands the genetic code by adding a new DNA base pair and is
designed to create optimized biologics, referred to as Synthorins.
A Synthorin is a protein optimized through incorporation of novel
amino acids encoded by the new DNA base pair that enables
site-specific modifications, which enhance the pharmacological
properties of these therapeutics. The company’s lead product
candidate, THOR-707, a variant of IL-2, is in development in
multiple tumor types as a single agent and in combination with an
immune checkpoint inhibitor. The company was founded based on
important discoveries in Dr. Floyd Romesberg’s lab at The Scripps
Research Institute. The company is headquartered in La Jolla,
Calif.
Corporate Development Contact: Enoch Kariuki,
Pharm.D.Synthorx, Inc.ekariuki@synthorx.com 858-750-4750
Media Relations Contact:Lauren FishCanale
Communicationslauren@canalecomm.com619-849-5386
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Apr 2023 to Apr 2024